A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer
Clinton Yam, Gaiane M. Rauch, Tanbin Rahman, Meghan Karuturi, Elizabeth E. Ravenberg, Jason B. White, Alyson R. Clayborn, Pamela McCarthy, Sausan Abouharb, Bora Lim, Jennifer K. Litton, David L. Ramírez, Sadia Saleem, James Stec, W. Fraser Symmans, Lei Huo, Senthil Damodaran, Ryan Sun, Stacy L. Moulder
Topics & Concepts
Triple-negative breast cancerMedicineBreast cancerInternal medicinePopulationBiomarkerClinical trialImmunohistochemistryOncologyCancerAntibody-drug conjugateAdverse effectPhases of clinical researchGastroenterologyAntibodyImmunologyMonoclonal antibodyChemistryEnvironmental healthBiochemistryHER2/EGFR in Cancer ResearchCancer-related Molecular PathwaysBreast Cancer Treatment Studies